D10627 inhibitors are a class of compounds designed to target a specific molecule or protein referred to by its code, D10627. While the specific biological role of D10627 is not commonly discussed in standard references, it is possible that it belongs to a class of proteins or enzymes involved in a particular biochemical pathway or cellular process. Inhibitors of D10627 would act by binding to this target and disrupting its normal function, which could involve enzymatic activity, protein-protein interactions, or other molecular mechanisms. Inhibitors are typically designed based on the structural features of the target, aiming to prevent its interaction with substrates or other molecules in its pathway.
The mechanism of action for D10627 inhibitors likely involves interference with critical regions of the target protein, such as an active site or binding domain. These inhibitors may either mimic the natural substrate of D10627 or bind to key regions that alter its conformation, rendering it inactive or significantly reducing its functionality. By inhibiting D10627, researchers can explore its role in various biological processes, including how it contributes to cellular functions like signal transduction, metabolism, or regulation of other proteins. Inhibition of D10627 could lead to changes in cellular behavior, providing insights into the broader pathways and systems in which this molecule is involved. These inhibitors are important tools for studying the biological significance of D10627 and for identifying its potential impact on biochemical processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D, a transcription inhibitor, directly inhibits Zfp930 by intercalating into DNA, preventing RNA polymerase II binding, and blocking transcription activation. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Alpha-Amanitin, an RNA polymerase II inhibitor, directly inhibits Zfp930 by binding to the enzyme and inhibiting RNA synthesis, leading to a decrease in transcriptional activity. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide, a transcription inhibitor, directly targets Zfp930 by inhibiting the activity of RNA polymerase II and disrupting the formation of the transcription initiation complex. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol, a cyclin-dependent kinase inhibitor, indirectly influences Zfp930 by disrupting cell cycle progression and CDK7-mediated phosphorylation, impacting transcriptional regulation. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB, a transcription elongation inhibitor, directly inhibits Zfp930 by blocking RNA polymerase II elongation, leading to the inhibition of transcriptional activation. | ||||||
Butyrolactone I | 87414-49-1 | sc-201533 sc-201533A | 200 µg 1 mg | $122.00 $514.00 | 1 | |
Butyrolactone I, a CDK inhibitor, indirectly influences Zfp930 by inhibiting cyclin-dependent kinases and impacting RNA polymerase II phosphorylation, affecting transcriptional regulation. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $69.00 $266.00 | 8 | |
Mycophenolic acid, an IMPDH inhibitor, indirectly influences Zfp930 by disrupting nucleotide biosynthesis, affecting RNA polymerase II function and transcriptional activation. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin, an RNA polymerase II inhibitor, directly inhibits Zfp930 by mimicking adenosine and terminating transcription, leading to the inhibition of gene expression. | ||||||
Flavopiridol Hydrochloride | 131740-09-5 | sc-207687 | 10 mg | $317.00 | ||
Flavopiridol HCl, a CDK inhibitor, indirectly influences Zfp930 by disrupting CDK7-mediated phosphorylation, impacting RNA polymerase II activity and transcriptional regulation. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $245.00 | ||
CX-5461, a RNA polymerase I inhibitor, indirectly influences Zfp930 by disrupting rRNA synthesis, impacting the cellular pool of ribosomes and affecting transcriptional regulation. | ||||||